1. Oridonin induces G2/M cell cycle arrest and apoptosis in human oral squamous cell carcinoma
   Han Wang et al, 2017, European Journal of Pharmacology CrossRef
2. Oridonin inhibits oral cancer growth and PI3K/Akt signaling pathway.
   Jing Yang et al, 2018, Biomed Pharmacother CrossRef
3. null
   Yi Chieh Lim et al, 2018 CrossRef
4. Coxsackievirus A6 Induces Cell Cycle Arrest in G0/G1 Phase for Viral Production.
   Zengyan Wang et al, 2018, Front Cell Infect Microbiol CrossRef
5. Structural modification of oridonin via DAST induced rearrangement
   Dong-Dong Luo et al, 2018, RSC Adv. CrossRef
6. Effect of ingredients from Chinese herbs on enterovirus D68 production
   Xiangling Meng et al, 2018, Phytotherapy Research CrossRef
7. Naturally occurring anti-cancer compounds: shining from Chinese herbal medicine.
   Hua Luo et al, 2019, Chin Med CrossRef
8. Prognostic role of long non-coding RNA TUG1 expression in various cancers: a meta-analysis
   Yongping Zhou et al, 2017, Oncotarget CrossRef
9. Oridonin: A Review of Its Pharmacology, Pharmacokinetics and Toxicity.
   Xiang Li et al, 2021, Front Pharmacol CrossRef
10. Recent progress of oridonin and its derivatives for cancer therapy and drug resistance
    Yong-Feng Guan et al, 2021, Med Chem Res CrossRef
11. Traditional Chinese Medicine has great potential as candidate drugs for lung cancer: A review.
    Zhicheng Wei et al, 2023, J Ethnopharmacol CrossRef
12. Recent advances in oridonin derivatives with anticancer activity
    Pedro J. M. Sobral et al, 2023, Front. Chem. CrossRef
13. Oridonin inhibits bladder cancer survival and immune escape by covalently targeting HK1
    Shuangjie Liu et al, 2024, Phytomedicine CrossRef
14. Inhibition of ALDOA‐ and ENO1‐Mediated Glycolysis of Oridonin as a Novel Antitumor Strategy of Non‐Small‐Cell Lung Cancer
    Tianming Lu et al, 2024, Advanced Therapeutics CrossRef
15. To Explore the Effect of Chinese Medicine Monomer Oridonin on Lung Malignant Tumor
    菊芳 蒲, 2024, TCM CrossRef
16. Enhancing cancer therapy: advanced nanovehicle delivery systems for oridonin
    Yilin Su et al, 2024, Front. Pharmacol. CrossRef